Bupropion + Naltrexone is a fixed-dose combination pill that contains two active ingredients: bupropion and naltrexone. The tablet is marketed for adults seeking weight-loss support and is also relevant to the management of addiction-related conditions such as smoking cessation. In Hong Kong, the product is classified as a prescription medication and must be prescribed by a qualified healthcare professional.
The combination leverages the distinct mechanisms of each component to address appetite regulation and reward pathways that underpin overeating and substance use.
Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI). By blocking the reabsorption of these neurotransmitters, it increases their levels in synaptic clefts, which can reduce cravings and improve mood. Naltrexone is an opioid receptor antagonist; it blocks µ-opioid receptors that are involved in the brain’s reward circuitry. When combined, the two agents produce a synergistic effect:
Together, they help to diminish both the physiological drive to eat and the psychological reinforcement that sustains unhealthy eating or smoking habits. Onset of action is typically within the first week, with peak therapeutic effects observed after several weeks of consistent dosing.
In Hong Kong, the combination is approved for chronic weight management in adults with a body mass index (BMI) ≥ 30 kg/m², or ≥ 27 kg/m² with at least one weight-related comorbidity (e.g., hypertension, dyslipidaemia, type 2 diabetes). The medication is intended as an adjunct to a reduced-calorie diet and increased physical activity.
Other off-label investigations (e.g., alcohol-use disorder) exist, but evidence remains limited. Healthcare providers should evaluate the risk-benefit profile for each individual.
If any of these conditions apply, a thorough assessment by a prescriber is essential before initiating therapy.
Patients should disclose all prescription, over-the-counter, and herbal products before starting therapy.
Dosing must be individualized by a prescriber based on blood pressure, seizure risk, and overall treatment response.
Regular follow-up visits enable dose adjustments, reinforcement of lifestyle changes, and early detection of adverse events.
This article provides educational information about Bupropion + Naltrexone and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
The fixed-dose tablet delivers a low dose of bupropion (8 mg) together with a higher dose of naltrexone (90 mg) in a single capsule, simplifying the regimen and ensuring consistent drug ratios that have been studied for weight-loss efficacy.
Patients with uncontrolled hypertension should avoid the combination. Those with well-managed blood pressure may be prescribed the drug after careful assessment and regular monitoring.
Bupropion and naltrexone are not typically screened for in standard workplace drug tests. However, any unexpected results should be discussed with the testing authority, providing a prescription note if needed.
Yes, provided you carry a valid prescription, the original pharmacy labeling, and declare the medication at customs if required by Hong Kong or the destination country's regulations.
Clinical studies show that noticeable weight reduction often begins within the first 8-12 weeks, but individual results vary and depend on adherence to diet and exercise recommendations.
Moderate alcohol consumption is permissible, but excessive intake may increase seizure risk and diminish the medication’s effectiveness. Discuss your drinking habits with your prescriber.
Take the tablet early in the morning and avoid late-day dosing. If insomnia persists, contact your healthcare provider for possible dose adjustment or alternative therapy.
Common fillers include lactose, microcrystalline cellulose, and magnesium stearate. If you have known sensitivities, verify the excipient list with your pharmacist.
No clinically significant interaction has been identified between the combination and hormonal contraceptives; however, always inform your clinician of all concurrent medications.
Coverage depends on individual health plans and the prescribed indication. Check with your insurer or hospital pharmacy for reimbursement details.
